Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)

• Status: Withdrawn
• Trial end date: 2019-03-12
• Target enrollment: 0
• Participant gender: All

Summary

Non-randomized phase I/II, open-labeled clinical study, 1-arm, multicenter, of docetaxel (T), cisplatin (P), 5-fluorouracil (F) and pembrolizumab every 21 days for 3 cycles followed by radiotherapy (RT) combined with carboplatin in untreated unresectable locally-advanced Head and Neck Squamous Cell Carcinoma (HNSCC).

The TPF and pembrolizumab combination will be called TP²F.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Antoine Lacassagne
• Collaborators: GERCOR - Multidisciplinary Oncology Cooperative Group; GORTEC; Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
• Treatments: Carboplatin; Cisplatin; Docetaxel; Pembrolizumab

Criteria

Inclusion Criteria:

To be eligible for participation in this trial, the subject should fulfill the following criteria:

1. Age > or = 18 and < 70 years years at the time of signing informed consent,

2. Histologically or cytologically confirmed head and neck squamous-cell carcinoma (oral cavity, oropharynx and hypopharynx) with locoregionally-advanced disease stage III or IV without metastasis, previously untreated,

3. Measurable disease based on RECIST 1.1,

4. Performance status of 0 or 1 on the ECOG Performance Scale,

5. Adequate organ function described in protocol section 4.2 - Inclusion criteria,

6. Tumors considered unresectable by a multidisciplinary team,

7. Available biopsy sample and HPV status,

8. Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required,

9. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 180 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year,

10. Male subjects should agree to use an adequate method of contraception or abstain from heterosexual activity starting with the first dose of study therapy through 180 days after the last dose of study therapy,

11. Patient willing and able to provide written informed consent/assent for the trial,

12. Patient affiliated with a health insurance system.

Exclusion criteria

The subject should not enter into the study if any of the following exclusion criteria are fulfilled:

1. Tumors of the nasopharynx, larynx and the nasal and paranasal cavities,

2. Hemorrhagic tumors, Protocol PICH_version 2.0 of 02 May 2018 Page 10 sur 127

3. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of treatment,

4. Before the first dose of trial treatment:

a) Had major surgery (< 4 weeks prior to the first dose), Note: If subject received major surgery, he must have recovered adequately from the toxicity and/or complications from the intervention before starting therapy,

5. Diagnosis of immunodeficiency (including HIV 1/2 positivity) or currently received systemic steroid therapy with dose superior to 10 mg/day of prednisone or equivalent or any other form of immunosuppressive therapy, within 7 days prior to the first dose of trial treatment,

6. Known history of active Bacillus Tuberculosis (TB),

7. Hypersensitivity to pembrolizumab or any of its excipients,

8. Any contraindication for receiving a treatment of docetaxel, cisplatin, 5-fluorouracil or carboplatin,

9. Hearing impairment or cardiorespiratory pathology with a contraindication of overhydration,

10. Currently received prophylactic treatment of phenytoin which could have an interaction with cisplatin, 5-fluorouracile or carboplatin or fosphenytoin which could have an interaction with carboplatin,

11. Currently received treatment of sorivudine or analogues (e.g. brivudine) with could have an interaction with 5-fluorouracile,

12. Complete known dihydropyrimidine dehydrogenase deficiency (DPD),

13. Clinically active cardiac disease or myocardial infarction within 6 months prior to the first dose of treatment,

14. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer,

15. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease-modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc…) is not considered a form of systemic treatment,

16. History of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis,

17. Active infection requiring systemic therapy,

18. History or current evidence of any condition, therapy, or laboratory abnormality that might influence the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator,

19. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial,

20. Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 180 days after the last dose of trial treatment,

21. Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent,

22. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected),

23. Received a live vaccine within 30 days of planned start of study therapy. Note:

Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed. However, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed,

24. Received prior organ transplant which may include an allogenic stem cell transplant,

25. People particularly vulnerable as defined in Articles L.1121-5 to -8 of the French Healthcare Code, including: person deprived of freedom by an administrative or judicial decision, adult being the object of a legal protection measure or outside a state to express their consent, pregnant or breastfeeding women.